Pruvonertinib
YK-029A is an orally active inhibitor of mutant EGFR, targeting to both the T790M mutations (EGFRT790M) and exon 20 insertion of EGFR (EGFRex20ins) . YK-029A exhibits significant antitumor activity, and results tumor regression in EGFRex20ins-driven PDX models[1].
Product Specifications
CAS Number
2064269-82-3
Product Name Alternative
YK-029A
UNSPSC
12352005
Target
EGFR
Type
Reference compound
Related Pathways
JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/yk-029a.html
Purity
99.50
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
C=CC(NC1=CC(NC2=NC=CC(C3=CN=C4C(C)=CC=CN43)=N2)=C(OC)C=C1N(CCN(C)C)C)=O
Molecular Formula
C27H32N8O2
Molecular Weight
500.60
References & Citations
[1]Liu B, et al. Discovery of YK-029A, a novel mutant EGFR inhibitor targeting both T790 M and exon 20 insertion mutations, as a treatment for NSCLC. Eur J Med Chem. 2023 Oct 5;258:115590.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
